For completeness, this latter group was monitored up to day 88 when all mice were positive for metastases (Fig. 4e), underlying that high levels of TRF2 correlate with a substantial delay in tumor progression following neoadjuvant therapy with taxanes. Here, TERF2 is linked to neoplasm.